Instil Bio, Inc.
TIL · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.03 | 0.01 | -0.02 | -0.03 |
| FCF Yield | -44.82% | -207.21% | -324.48% | -9.92% |
| EV / EBITDA | -3.29 | -0.87 | -0.54 | -11.53 |
| Quality | ||||
| ROIC | -28.39% | -28.42% | -44.98% | -27.36% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.75 | 0.53 | 0.81 | 0.78 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | – |
| Free Cash Flow Growth | 45.76% | 61.21% | -47.11% | -123.75% |
| Safety | ||||
| Net Debt / EBITDA | -1.27 | -0.53 | -0.17 | 0.24 |
| Interest Coverage | -8.18 | -17.38 | -109.49 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -66.63 | -93.02 | -143.82 | -738.49 |